SG11202111972YA - Solid forms of a glyt1 inhibitor - Google Patents

Solid forms of a glyt1 inhibitor

Info

Publication number
SG11202111972YA
SG11202111972YA SG11202111972YA SG11202111972YA SG11202111972YA SG 11202111972Y A SG11202111972Y A SG 11202111972YA SG 11202111972Y A SG11202111972Y A SG 11202111972YA SG 11202111972Y A SG11202111972Y A SG 11202111972YA SG 11202111972Y A SG11202111972Y A SG 11202111972YA
Authority
SG
Singapore
Prior art keywords
compound
ppm
solid
solid form
magnetic resonance
Prior art date
Application number
SG11202111972YA
Other languages
English (en)
Inventor
Peter Sieger
Joe Ju Gao
Bing-Shiou Yang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SG11202111972YA publication Critical patent/SG11202111972YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202111972YA 2019-05-01 2020-04-30 Solid forms of a glyt1 inhibitor SG11202111972YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841401P 2019-05-01 2019-05-01
PCT/US2020/030580 WO2020223419A1 (en) 2019-05-01 2020-04-30 Solid forms of a glyt1 inhibitor

Publications (1)

Publication Number Publication Date
SG11202111972YA true SG11202111972YA (en) 2021-11-29

Family

ID=70740812

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111972YA SG11202111972YA (en) 2019-05-01 2020-04-30 Solid forms of a glyt1 inhibitor

Country Status (25)

Country Link
US (2) US11447474B2 (https=)
EP (1) EP3962911A1 (https=)
JP (2) JP7513349B2 (https=)
KR (1) KR20220004174A (https=)
CN (1) CN113784966B (https=)
AR (1) AR118839A1 (https=)
AU (1) AU2020266566B2 (https=)
BR (1) BR112021020883A2 (https=)
CA (1) CA3138288A1 (https=)
CL (2) CL2021002837A1 (https=)
CO (1) CO2021014260A2 (https=)
CR (1) CR20210545A (https=)
DO (1) DOP2021000224A (https=)
EA (1) EA202192925A1 (https=)
EC (1) ECSP21082195A (https=)
IL (1) IL287630A (https=)
JO (1) JOP20210295A1 (https=)
MA (1) MA55801A (https=)
MX (1) MX2021013341A (https=)
PE (1) PE20212263A1 (https=)
PH (1) PH12021552741A1 (https=)
SG (1) SG11202111972YA (https=)
TW (1) TW202106680A (https=)
UA (1) UA129159C2 (https=)
WO (1) WO2020223419A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
EA202192925A1 (ru) * 2019-05-01 2022-03-23 Бёрингер Ингельхайм Интернациональ Гмбх Твердые формы ингибитора glyt1
US11813257B2 (en) 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
MX2023001818A (es) * 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking
WO2025140479A1 (zh) * 2023-12-29 2025-07-03 苏州科睿思制药有限公司 Iclepertin的晶型及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
RS20060190A (sr) * 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
CA2745690A1 (en) * 2008-12-04 2010-06-10 Evgeny Zlotinikov Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
EP2381941A4 (en) * 2008-12-29 2012-08-01 Univ Vanderbilt 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US9012489B2 (en) 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
IL270155B (en) * 2017-04-27 2022-07-01 Takeda Pharmaceuticals Co Heterocyclic compound
EA202192925A1 (ru) * 2019-05-01 2022-03-23 Бёрингер Ингельхайм Интернациональ Гмбх Твердые формы ингибитора glyt1
MX2023001818A (es) * 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) * 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking

Also Published As

Publication number Publication date
CN113784966B (zh) 2024-07-19
JOP20210295A1 (ar) 2023-01-30
JP2024100792A (ja) 2024-07-26
DOP2021000224A (https=) 2021-12-15
TW202106680A (zh) 2021-02-16
NZ781254A (en) 2025-03-28
CR20210545A (es) 2021-12-23
JP7714727B2 (ja) 2025-07-29
JP2022530630A (ja) 2022-06-30
CL2021002837A1 (es) 2022-07-29
PH12021552741A1 (en) 2022-07-11
PE20212263A1 (es) 2021-11-29
CA3138288A1 (en) 2020-11-05
EA202192925A1 (ru) 2022-03-23
EP3962911A1 (en) 2022-03-09
ECSP21082195A (es) 2021-12-30
WO2020223419A1 (en) 2020-11-05
AU2020266566B2 (en) 2025-11-06
MX2021013341A (es) 2021-11-17
US11447474B2 (en) 2022-09-20
MA55801A (fr) 2022-03-09
US20220332710A1 (en) 2022-10-20
AR118839A1 (es) 2021-11-03
CL2024000829A1 (es) 2024-09-27
KR20220004174A (ko) 2022-01-11
IL287630A (en) 2021-12-01
US20200347041A1 (en) 2020-11-05
AU2020266566A1 (en) 2021-11-11
JP7513349B2 (ja) 2024-07-09
CO2021014260A2 (es) 2021-10-29
UA129159C2 (uk) 2025-01-29
BR112021020883A2 (pt) 2022-04-19
CN113784966A (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
US11447474B2 (en) Solid forms of a GlyT1 inhibitor
US10723730B2 (en) Solid forms of a selective CDK4/6 inhibitor
JP5315244B2 (ja) アザビシクロヘキサン誘導体の使用
KR101694551B1 (ko) 로티고틴의 다형 형태
CN103958469A (zh) 一种新的普利多匹定盐酸盐多晶型形态
EP2297152A1 (en) Anhydrous crystal form of orvepitant maleate
RS55511B1 (sr) Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba
JP2009514801A (ja) 電位依存性ナトリウムチャネルの調節因子としての第四級α−アミノカルボキサミド誘導体
EA045384B1 (ru) Твердые формы ингибитора glyt1
WO2005089353A2 (en) (s)-amlodipine malate
JP5077232B2 (ja) ベンゾオキサジアゾール誘導体の結晶
HU231016B1 (hu) Idelalisib új polimorf és szolvát formája
MX2007006842A (es) Derivados de arilpiperazina y uso de los mismos como ligantes receptores de 5-ht1a.
BG62966B1 (bg) Нови полиморфни форми на лезопитрон дихидрохлорида и неговите хидратни форми, методи за тяхното получаване и състави, които ги съдържат
NZ710138B2 (en) Solid forms of a selective cdk4/6 inhibitor
JP2013507420A (ja) パルドプルノックスの多形